What is Iridex's market cap?

Iridex (IRIX) has a market capitalization of $10.7M and trades on NASDAQ.

Who are Iridex's competitors?

Iridex's key competitors include Bausch + Lomb, Harrow, Inc. Common Stock, LENSAR, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Iridex partner with?

Iridex's notable partners include Topcon Corporation, Lumenis, Alcon.

Where is Iridex headquartered?

Iridex is headquartered in United States of America and employs approximately 139 people. It has been publicly traded since 1996.

Iridex (IRIX) Stock Fundamentals & Financials

Iridex Corp is an ophthalmic medical technology company that develops and commercializes laser-based systems for treating sight-threatening eye conditions.

Market cap

$10.66M-51.4%

Earnings

Q2 2026 report

August 18, 2026

Revenue$12.6MMiss by $1.0M EPS-$0.07Miss by $0.06

Read the full report

Next report

Nov 17, 2026 (in 2 months)

Revenue estimate$12.6M

EPS estimate-$0.04

Competitors

By market cap

Regeneron Pharmaceuticals$79.7B+28.5%

Bausch + Lomb$6.1B+13.9%

HRO

Harrow$1.3B-19.7%

Lineage Cell Therapeutics$270.6M-14.7%

RxSight, Inc.$224.6M-38.7%

LENSAR, Inc.$87.0M-42.5%

Aldeyra Therapeutics$82.6M-71.9%

Iridex$10.7M-51.4%

By revenue growth

HRO

Harrow+21.1%

Regeneron Pharmaceuticals+9.3%

Bausch + Lomb+8.9%

LENSAR, Inc.+3.3%

RxSight, Inc.-13.2%

By net margin

LENSAR, Inc.57.57%+142pp

Regeneron Pharmaceuticals27.86%-3.5pp

Bausch + Lomb-3.21%+2.4pp

HRO

Harrow-19.75%+4.4pp

RxSight, Inc.-36.8%-14.9pp

Profile

Iridex Corp is an ophthalmic medical technology company that develops and commercializes laser-based systems for treating sight-threatening eye conditions. The company's core value proposition centers on its proprietary MicroPulse and Endpoint Management technologies, which provide tissue-sparing, subvisible laser therapy for glaucoma and retinal diseases. By offering a safer clinical profile compared to traditional high-energy continuous-wave lasers, Iridex enables physicians to stabilize vision while minimizing collateral tissue damage.

Competitive position

A specialized provider of tissue-sparing ophthalmic lasers, leveraging proprietary microsecond-pulse technology to compete against traditional high-energy photocoagulation systems.

GeographiesUnited States, Germany, Italy, United Kingdom, India, Global

Customer segmentsHealthcare Providers, Surgical Centers, Specialized Medical Practices

Business modelRazor-and-blade, Manufacturing, Service and Maintenance

SuppliersLaser component manufacturers, Medical-grade plastic suppliers, Electronic component providers, Specialized optical fiber suppliers

CustomersHospitals, Ambulatory Surgical Centers, Ophthalmic clinics, Independent medical distributors

CountryUnited States of America

Listed1996

Employees139.0

CEOPatrick Mercer

SectorHealthcare

IndustryMedical - Devices

Websiteiridex.com

FilingsSEC EDGAR

FAQ

What is Iridex's market cap?: Iridex (IRIX) has a market capitalization of $10.7M and trades on NASDAQ.
Who are Iridex's competitors?: Iridex's key competitors include Bausch + Lomb, Harrow, Inc. Common Stock, LENSAR, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Iridex partner with?: Iridex's notable partners include Topcon Corporation, Lumenis, Alcon.
Where is Iridex headquartered?: Iridex is headquartered in United States of America and employs approximately 139 people. It has been publicly traded since 1996.